Lead Product(s) : FX06
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Assistance Publique Hopitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable
F4 Pharma Starts Clinical Trial with FX06 in Frace to Treat Most Severely Affected Covid-19 Patients
Details : Company has announced that the randomized, double-blind, placebo-controlled FX-COVID trial which is conducted by AP-HP (Assistance Publique – Hopitaux de Paris), is set up to confirm the efficacy and safety of FX06 in hospitalized patients receiving me...
Product Name : FX06
Product Type : Peptide
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : FX06
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Assistance Publique Hopitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable